Charge-Shifting Copolymers of 2-( N , N -Dimethylamino)Ethyl Acrylate and 2-Hydroxyethyl Acrylate via RAFT Polymerization: Balancing the Charge Content and Biological Response
Source abstract
Abstract
High Resolution Image Download MS PowerPoint Slide Synthetic polycations are key components for engineering polyelectrolyte complexes with wide-ranging biomedical potential. However, the high cytotoxicity of fully charged polycations remains a major limitation for clinical applications. To address this challenge, we report on polycations derived from the cationic monomer 2-( N,N -dimethylaminoethyl) acrylate (DMAEA), which gradually loses charge through hydrolysis, thereby reducing their charge density over time. The overall charge fraction (from 100% to 20%) was further controlled through copolymerization with the neutral comonomer 2-hydroxyethyl acrylate (HEA). The selected conditions of reversible addition–fragmentation chain transfer (RAFT) copolymerization, specifically protonation of DMAEA with trifluoroacetic acid to mask its tertiary amino groups, enabled a precise control over the characteristics of the copolymers (termed D/H) up to 75% conversions, with close agreement between theoretical and experimental molecular weights up to 100 000 g/mol, consistently low dispersities (<1.2), and an excellent match between the theoretical and actual copolymer compositions. Hydrolysis studies at pH 7.4 showed that increasing the HEA content in D/H copolymers from 20 to 50 mol % led to only a 10% increase in the hydrolysis over 3 weeks. Isothermal titration calorimetry analysis demonstrated that all copolymers retained their ability to complex with heparin, with binding strength comparable to that of commonly used polycations. Importantly, the cytotoxicity of D/H copolymers toward human umbilical vein endothelial cells (HUVECs) decreased with increasing HEA content, reaching more than 80% cell viability at a relatively high concentration of 30 μg/mL. These findings demonstrate that D/H copolymers combine precise structural control with reduced cytotoxicity, making them promising candidates for biomedical polyelectrolyte platforms.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Polymer Synthesis and Characterization · Hydrogels: synthesis, properties, applications · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovsky nam. 2, Prague 162 00 Prague 6, Czech Republic
NanoBioMedical Centre, Adam Mickiewicz University, Wszechnicy Piastowskiej 3, Poznań 61-614, Poland
Laboratory of Biomaterials and Tissue Engineering, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, Prague 142 00 Prague 4, Czech Republic
Funding
Grantová Agentura Ceské Republiky · European Commission
References (64)
Show source-provided references
1. 10.1016/S0168-3659(98)00015-710.1016/S0168-3659(98)00015-7 ↗
2. 10.1021/ma051270a10.1021/ma051270a ↗
3. 10.1016/S1461-5347(99)00186-810.1016/S1461-5347(99)00186-8 ↗
4. 10.1126/science.277.5330.123210.1126/science.277.5330.1232 ↗
5. 10.1021/la061638c10.1021/la061638c ↗
6. 10.1016/0040-6090(92)90417-A10.1016/0040-6090(92)90417-A ↗
7. 10.1002/masy.1991046014510.1002/masy.19910460145 ↗
8. 10.1021/cr400531v10.1021/cr400531v ↗
9. 10.1021/jp045070x10.1021/jp045070x ↗
10. 10.1021/ma047414n10.1021/ma047414n ↗
11. 10.1021/ma025837o10.1021/ma025837o ↗
12. 10.1021/ma001720t10.1021/ma001720t ↗
13. 10.1021/bm400221r10.1021/bm400221r ↗
14. 10.1039/b804953j10.1039/b804953j ↗
15. 10.1021/acs.macromol.9b0227210.1021/acs.macromol.9b02272 ↗
16. 10.1021/acs.macromol.5b0219110.1021/acs.macromol.5b02191 ↗
17. 10.1021/acs.macromol.8b0093110.1021/acs.macromol.8b00931 ↗
18. 10.1039/C7PY00219J10.1039/C7PY00219J ↗
19. 10.1016/0014-3057(89)90054-210.1016/0014-3057(89)90054-2 ↗
20. 10.1021/bm200219e10.1021/bm200219e ↗
21. 10.1016/j.progpolymsci.2016.05.00410.1016/j.progpolymsci.2016.05.004 ↗
22. 10.1016/j.biomaterials.2009.10.03310.1016/j.biomaterials.2009.10.033 ↗
23. 10.1016/S0142-9612(02)00445-310.1016/S0142-9612(02)00445-3 ↗
24. 10.1242/jcs.94.3.55310.1242/jcs.94.3.553 ↗
25. 10.1016/j.ijpharm.2017.02.04810.1016/j.ijpharm.2017.02.048 ↗
26. 10.1021/acs.macromol.3c0122310.1021/acs.macromol.3c01223 ↗
27. 10.1039/D2PY01012G10.1039/D2PY01012G ↗
28. 10.1016/S0032-3861(96)00532-010.1016/S0032-3861(96)00532-0 ↗
29. 10.1021/acsmacrolett.8b0042010.1021/acsmacrolett.8b00420 ↗
30. 10.1002/marc.20029001210.1002/marc.200290012 ↗
31. 10.1016/j.polymer.2010.08.01510.1016/j.polymer.2010.08.015 ↗
32. 10.1002/marc.20240064010.1002/marc.202400640 ↗
33. 10.1038/ncomms290510.1038/ncomms2905 ↗
34. 10.1002/jbm.a.3562910.1002/jbm.a.35629 ↗
35. 10.1002/pola.2673010.1002/pola.26730 ↗
36. 10.1021/acs.biomac.0c0069810.1021/acs.biomac.0c00698 ↗
37. 10.1002/marc.20160064110.1002/marc.201600641 ↗
38. 10.1021/acsomega.9b0373410.1021/acsomega.9b03734 ↗
39. 10.1021/ja01237a05210.1021/ja01237a052 ↗
40. 10.1021/ja01213a03110.1021/ja01213a031 ↗
41. 10.1016/j.actbio.2023.09.00410.1016/j.actbio.2023.09.004 ↗
42. 10.1039/D4PY00270A10.1039/D4PY00270A ↗
43. 10.1002/9783527622757.ch310.1002/9783527622757.ch3 ↗
44. 10.1021/acsmacrolett.8b0081310.1021/acsmacrolett.8b00813 ↗
45. 10.3390/polym1305077810.3390/polym13050778 ↗
46. 10.1002/pola.2876310.1002/pola.28763 ↗
47. 10.1039/C7PY00185A10.1039/C7PY00185A ↗
48. 10.1016/j.progpolymsci.2017.11.00210.1016/j.progpolymsci.2017.11.002 ↗
49. 10.1021/ma101122b10.1021/ma101122b ↗
50. 10.1074/jbc.M111.22811410.1074/jbc.M111.228114 ↗
51. 10.3390/biom1411142110.3390/biom14111421 ↗
52. 10.1021/acs.biomac.2c0092610.1021/acs.biomac.2c00926 ↗
53. 10.1016/j.jcis.2025.13786510.1016/j.jcis.2025.137865 ↗
54. 10.1016/j.eurpolymj.2016.08.02110.1016/j.eurpolymj.2016.08.021 ↗
55. 10.1016/j.taap.2019.05.01110.1016/j.taap.2019.05.011 ↗
56. 10.1002/(SICI)1099-1263(199611)16:6<533::AID-JAT391>3.0.CO;2-B10.1002/(SICI)1099-1263(199611)16:6<533::AID-JAT391>3.0.CO;2-B ↗
57. 10.1016/j.bioactmat.2020.12.00110.1016/j.bioactmat.2020.12.001 ↗
58. 10.1177/096032711984692410.1177/0960327119846924 ↗
59. 10.1002/jgm.77310.1002/jgm.773 ↗
60. 10.1039/D1EN01156A10.1039/D1EN01156A ↗
61. 10.1021/bm900012410.1021/bm9000124 ↗
62. 10.1039/c000190b10.1039/c000190b ↗
63. 10.1016/j.ijbiomac.2023.12385410.1016/j.ijbiomac.2023.123854 ↗
64. 10.1021/acs.biomac.4c0000710.1021/acs.biomac.4c00007 ↗